Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06531941 · ClinicalTrials.gov registry record · Phase 2

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

A Phase 2 study of Hypoparathyroidism, sponsored by MBX Biosciences.

Active
Registry status
Phase 2
Development phase
60
Enrollment target
20
Study locations

NCT06531941 is a Phase 2 study of Hypoparathyroidism that is active but no longer recruiting, run by MBX Biosciences. The registered enrollment target is 60 participants, below the 194-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06531941, a Phase 2 study of Hypoparathyroidism, is active but no longer recruiting, sponsored by MBX Biosciences.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.

Conditions Studied

Hypoparathyroidism

Interventions

  • DRUG 400 µg of MBX 2109 once-weekly by subcutaneous injection
  • DRUG 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection

Study Locations (20)

Texas

  • MBX Biosciences Investigational Site - Dallas
  • MBX Biosciences Investigational Site - El Paso
  • MBX Biosciences Investigational Site - Fort Worth
  • MBX Biosciences Investigational Site - Round Rock
  • MBX Biosciences Investigational Site - San Antonio
  • MBX Biosciences Investigational Site - Weslaco

New York

  • MBX Biosciences Investigational Site - Albany
  • MBX Biosciences Investigational Site - New York
  • MBX Biosciences Investigational Site - The Bronx

Nevada

  • MBX Biosciences Investigational Site - Las Vegas
  • MBX Biosciences Investigational Site - Reno

Buenos Aires

  • MBX Biosciences Investigational Site - Ciudad Autonoma de Buenos Aires
  • MBX Biosciences Investigational Site - Ciudad Autonoma de Buenos Aires

Florida

  • MBX Biosciences Investigational Site - Miami

Georgia

  • MBX Biosciences Investigational Site - Macon

Mississippi

  • MBX Biosciences Investigational Site - Jackson

Missouri

  • MBX Biosciences Investigational Site - St Louis

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-10-31
Est. Completion 2027-05-27
Phase Phase 2

Sponsor

MBX Biosciences

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06531941

The ClinicalTrials.gov registry entry for NCT06531941 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 194-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (69% lower). The listed sponsor is MBX Biosciences, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which 400 µg of MBX 2109 once-weekly by subcutaneous injection is the first listed.

NCT06531941 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, New York, Nevada.

Frequently Asked Questions

What is clinical trial NCT06531941 about?

NCT06531941 is a clinical study titled "Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism". The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.

What is the current status of trial NCT06531941?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-10-31. Estimated completion is 2027-05-27.

What conditions does trial NCT06531941 study?

This clinical trial studies the following conditions: Hypoparathyroidism.

What interventions are being tested in trial NCT06531941?

The interventions under investigation include: 400 µg of MBX 2109 once-weekly by subcutaneous injection (DRUG), 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection (DRUG).

Who is sponsoring clinical trial NCT06531941?

This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06531941 being conducted?

This trial has 20 study locations across Florida, Georgia, Mississippi, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypoparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypoparathyroidism

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.